New Triple-Threat therapy aims to shrink tumors for liver transplant
NCT ID NCT07059494
Summary
This study is testing a three-part treatment to control liver cancer in people waiting for a liver transplant. It combines a targeted radiation treatment (Y-90) with two intravenous drugs (atezolizumab and bevacizumab). The goal is to shrink or stabilize tumors to help patients either stay eligible for a transplant or become eligible, depending on their starting point.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Icahn School of Medicine at Mount Sinai
RECRUITINGNew York, New York, 10029, United States
Contact
Conditions
Explore the condition pages connected to this study.